Stocks Health care PTGX
NASDAQ · Health careProtagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc brought in $282M of revenue over the twelve months to June 30, 2026, up 34.8% from a year earlier. Net income was $82.9M, a net margin of 29.4%. Operating cash flow minus capital spending left $56.1M of free cash flow in fiscal 2025. At June 30, 2026 it held $420.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What Protagonist Therapeutics, Inc does
Protagonist Therapeutics, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PTGX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $46M | -$130.1M | -$2.05 | $56.1M |
| 2024 | $434.4M | $275.2M | $4.23 | $182.8M |
| 2023 | $60M | -$79M | -$1.39 | -$70.8M |
| 2022 | $26.6M | -$127.4M | -$2.60 | -$108.9M |
| 2021 | $27.4M | -$125.6M | -$2.71 | -$109M |
| 2020 | $28.6M | -$66.2M | -$1.92 | -$73M |
Where PTGX ranks in Health care
Latest SEC filings
What Protagonist Therapeutics, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026Form S-8 POS filing S-8 POS
- August 5, 2026Form S-8 POS filing S-8 POS
- August 5, 2026Form S-8 POS filing S-8 POS
- August 5, 2026Form S-8 POS filing S-8 POS
- August 5, 2026Form S-8 POS filing S-8 POS
- August 5, 2026Form S-8 POS filing S-8 POS
- August 5, 2026Form S-8 POS filing S-8 POS
- August 5, 2026Form S-8 POS filing S-8 POS
What is PTGX worth? A DCF from its reported cash flow
Insider trades
What the people running Protagonist Therapeutics, Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $18.2M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 10, 2026 | Patel Dinesh V Ph DPresident and CEO, Director | Exercised options | 7,278 | $157.1K |
| September 10, 2026 | Patel Dinesh V Ph DPresident and CEO, Director | Soldpre-planned (10b5-1) | 7,278 | $1M |
| September 9, 2026 | Patel Dinesh V Ph DPresident and CEO, Director | Exercised options | 63,548 | $1.4M |
| September 9, 2026 | Patel Dinesh V Ph DPresident and CEO, Director | Soldpre-planned (10b5-1) | 63,548 | $9.3M |
| September 8, 2026 | Patel Dinesh V Ph DPresident and CEO, Director | Exercised options | 54,174 | $1.2M |
| September 8, 2026 | Patel Dinesh V Ph DPresident and CEO, Director | Soldpre-planned (10b5-1) | 54,174 | $7.9M |
| September 3, 2026 | Patel Dinesh V Ph DPresident and CEO, Director | Gave as a gift | 510 | - |
Questions about PTGX
What does Protagonist Therapeutics, Inc do?
Protagonist Therapeutics, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PTGX.
Is Protagonist Therapeutics, Inc profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $82.9M on revenue of $282M, a net margin of 29.4%.
How much revenue does Protagonist Therapeutics, Inc make?
Over the twelve months to June 30, 2026 Protagonist Therapeutics, Inc reported revenue of $282M. That is 34.8% more than a year earlier.
When did Protagonist Therapeutics, Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 10, 2026.
Similar companies
Compare PTGX with
Follow PTGX
Get an email when Protagonist Therapeutics, Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow PTGX: get an email when it filesWhere the numbers come from
Financial figures are the values Protagonist Therapeutics, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.